Glycoprotein hormone receptors such as the lutropin/chorionic gonadotropin receptor (LHR) are characterized by a large N-terminal ectodomain (ECD), which is responsible for hormone-receptor interactions. For the closely related TSH receptor (TSHR), it has been proposed that the ECD also serves as a tethered inverse agonist. However, the exact role of the LHR-ECD for receptor activation remains elusive. Functional analysis of N-terminally truncated LHR mutants expressed in COS-7 cells revealed that the LHR-ECD does not act as an inverse agonist but facilitates active LHR conformations. This notion is supported by two observations: first, removal of the ECD tended to decrease basal LHR activity and secondly, mutationally induced constitutive receptor activity was diminished for most activating mutations in LHR lacking the ECD. In addition, swapping of the LHR-ECD for the ECD of the closely related TSHR was not sufficient to restore constitutive receptor activity induced by naturally occurring activating heptahelical LHR mutations. Thus, the ECD stabilizes an activation-competent conformation of the heptahelical region. While the full-length LHR fused to the cognate agonist, human chorionic gonadotropin (hCG), showed increased basal activity, fusion proteins between hCG and Nterminally truncated LHR did not yield constitutive receptor activity suggesting an important role of the ECD also for agonist-dependent LHR activity. Our experiments strengthen the concept of a major contribution of the LHR-ECD in the activation mechanism apart from hormone binding and provide evidence for a cooperative model with structural and functional interactions of the ECD and the transmembrane domain.
Introduction
The receptors for glycoprotein hormones -luteinizing hormone, human chorionic gonadotropin (hCG), follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH) -belong to the subfamily of leucine-rich repeat (LRR)-containing G proteincoupled receptors (LGR) comprising at least eight structurally related human members (Herpin et al. 2004) . A major feature of glycoprotein hormone receptors is the large N-terminal ectodomain (ECD) harboring the structural hallmark of LRR motifs (Fan & Hendrickson 2005) . The crystal structure of human FSH complexed with the N-terminal hormone-binding domain of the human FSH receptor reveals that the LRR domain is composed of ten irregular LRR that all participate in hormone binding (Fan & Hendrickson 2005) . Glycoprotein hormones are heterodimers composed of a common a-subunit and a hormone-specific b-subunit that is responsible for receptor specificity. Yet, both subunits interact with the ECD , Hong et al. 1999a ,b, Fan & Hendrickson 2005 . Although the ECD is responsible for specificity and affinity of ligand-binding (Xie et al. 1990 , Braun et al. 1991 , Moyle et al. 1994 , Bhowmick et al. 1996 , Thomas et al. 1996 , Hong et al. 1999a ,b, Ascoli et al. 2002 , Smits et al. 2003 , Vassart et al. 2004 , Fan & Hendrickson 2005 , and G protein activation is mediated by the transmembrane domain (TMD; Ascoli et al. 2002 , Vassart et al. 2004 , the activation mechanism of glycoprotein hormone receptors is still unclear.
Several mechanisms of receptor activation have been proposed. According to one model, the glycoprotein hormone is bound by the ECD, so that distinct portions of the hormone interact with and activate the TMD. This model suggests that once the cognate ligand is bound by the ECD, residues in the hormone, most likely in the common a-subunit of the glycoprotein hormones, interact with conserved amino acids present in the serpentine portion of their receptors. As a result, the cAMP signaling cascade common to all glycoprotein hormone receptors is activated. This mechanism is supported by the fact that antibodies against residues of the a-subunit of hCG can prevent receptor activation without affecting hormone binding of the lutropin/ chorionic gonadotropin receptor (LHR)-ECD (Couture et al. 1996) . In agreement with this hypothesis, previous studies have demonstrated that hCG and peptides derived from the hCG a-chain can directly activate an LHR variant lacking the ECD (Ji & Ji 1991 , Kundu et al. 1996 . In a second model, particularly proposed for the TSH receptor (TSHR), the ECD serves as an inverse agonist stabilizing the transmembrane helices in an inactive conformation. This model implies that hormone binding and activating mutations disengage the inhibitory ECD-TMD interaction (Zhang et al. 1995 , Van Sande et al. 1996 , Vlaeminck-Guillem et al. 2002 and is supported by findings that removal of the complete ECD leads to high constitutive receptor activity (Zhang et al. 2000) . Consistent with this hypothesis, deletion of portions of the ECD (Zhang et al. 1995) or activating mutations within the ECD can result in elevated basal activity. In a third scenario, binding of the hormone to the ECD leads to a conformational change of the receptor so that the ECD is able to act as an endogenous agonist on the TMD. This model is supported by findings that mutations of certain amino acid residues in the C-terminal end of the ECD impair ligand-induced receptor activation without affecting receptor expression or hormone binding (Alvarez et al. 1999) . Moreover, deletion of the N-terminal part of the ECD abrogates constitutive receptor activity caused by an activating mutation in the ECD (Sangkuhl et al. 2002) . A combination of the second and third model gives rise to an additional mechanism implying that the ECD initially acts as an inverse agonist, but changes its conformation to become an agonist by hormone binding or activating mutations (Vlaeminck--Guillem et al. 2002) .
Here, we examined the role of the ECD for the activation of the LHR. N-terminally modified LHR mutants were generated by site-directed mutagenesis, domain deletion and/or domain swapping. Mutant receptors were functionally analyzed by determining receptor protein expression and insertion into the cell membrane as well as basal and agonist-induced cAMP accumulation. Our results suggest that the LHR-ECD is a major factor for signaling in response to agonist or activating mutations by stabilizing an activation-competent conformation of the heptahelical receptor portion.
Materials and methods

Materials
Cell culture media were purchased from PAA Laboratories (Pasching, Austria). Restriction enzymes were obtained from Fermentas GmbH (St Leon-Rot, Germany) and New England Biolabs GmbH (Frankfurt am Main, Germany). QUIKCHANGE site-directed mutagenesis kit and Pfu Turbo DNA polymerase were provided by Stratagene (La Jolla, CA, USA). METAFEC-TENE transfection reagent was obtained from Biontex (Munich, Germany). Forskolin was provided by Biotrend (Cologne, Germany). Purified hCG was purchased from Calbiochem (Schwalbach, Germany). Horse radish peroxidase (HRP)-labeled and unlabeled rat monoclonal anti-haemagglutinin (HA) antibody (3F10), mouse monoclonal anti-HA antibody (12CA5), FUGENE transfection reagent and COMPLETE MINI protease inhibitor cocktail were obtained from Roche Diagnostics. HRP-conjugated anti-mouse IgG (A-4416), HRP-labeled anti-rabbit antibody (A-6154), fluorescein isothiocyanate-conjugated anti-rat IgG (F-1763), 3-isobutyl-1-methylxanthine and bTSH were obtained from Sigma. Rabbit antiserum against CGb of hCG was kindly provided by Irving Boime (Washington University, St Louis, MO, USA). ROTI-BLOCK blocking reagent was obtained from Roth (Karlsruhe, Germany). HYBOND C EXTRA and enhanced chemi luminescence (ECL) detection system were purchased from Amersham Biosciences. DC PROTEIN ASSAY was provided by Bio-Rad Laboratories GmbH. Ten percent phosphate-buffered formalin solution was provided by J T Baker (Deventer, The Netherlands). 1-STEP TURBO TMB-ELISA solution was purchased from Pierce Biotechnology (Rockford, IL, USA).
Construction of mutant LHR
The cDNA of the hLHR and hTSHR was subcloned into the expression vector pcDps (LHR-pcDps, TSHRpcDps) as described previously (Biebermann et al. 1997 , Schulz et al. 1999 . In order to permit immunological detection, an HA-tag (YPYDDVPDYA) was inserted into the wild type hTSHR downstream of amino acid 21 and into the wild type hLHR downstream of amino acid 26 by two-step PCR. The cDNA of hV2LHR integrated into the pcDps-vector was kindly provided by Torsten Schöneberg (Sangkuhl et al. 2002 ; Table 1 ). Point mutations resulting in naturally occurring activating TMD-mutations (Table 1) were integrated into LHR-pcDps by PCR-based site-directed mutagenesis and a restriction fragment replacement strategy. To generate TSHR-LHR chimeras, an EcoRV site was integrated at nucleotide 1230 of the hTSHR (GACATA/GATATC) and at nucleotide 1065 of the hLHR (GACATT/GATATC) allowing the subcloning of a TSHR-pcDps-fragment encoding for the complete TSHR-ECD into LHR-pcDps by AvrII and EcoRV. To create V2hingeLHR, a PCR fragment encoding for the ECD of the V 2 R and the amino acid residues 270-357 of the hLHR and ending with an EcoRV site was inserted into V2LHR over the NheI and EcoRV sites. A singlechain hCG variant composed of the b-subunit genetically fused to the a-subunit (CGba) was constructed in the laboratory of Irving Boime (Sugahara et al. 1995) . This single-chain hCG was shown to exhibit similar binding activity as the native heterodimer, but displayed an increased biological activity in vitro and in vivo compared with the native hCG (Sugahara et al. 1995) . A PCR fragment encoding for a small non-coding sequence with a BglII site, the single-chain hCG, an HA-tag, and ending with a NheI site in the V 2 R sequence was generated by overlapping PCR and fused to the V2LHR in pcDps over BglII and NheI in order to generate CGba-V2LHR. To create a full-length wild type receptor bound to single-chain hCG (CGba-LHR wt), CGba-V2LHR-pcDps and LHR-pcDps were digested with BglII and NheI and defined restriction fragments were combined. A flexible linker composed of the C-terminal end of CGb (CTP; aa 116-145) was inserted between the single-chain hCG and the HA-tag in CGba-CTP-LHR wt and CGba-CTP-V2LHR in two steps: first, an EcoRV restriction site (GATATC) was introduced at the 3 0 -end of the CGa sequence in CGba-LHR wt and CGba-V2LHR by site-directed mutagenesis. In a second step, a PCR-fragment encoding for amino acid (aa) 116 to 145 of CGb was subcloned into the EcoRV site of CGba-CTP-LHR wt-pcDps and CGba-V2LHR-pcDps. In order to design hormone-receptor fusion proteins lacking certain LRR, various portions within the LRR domain were deleted in CGba-LHR wt by using the twostep PCR technique. The detailed strategy of construction of each construct is available upon request. The correctness of all constructs was confirmed by dideoxy DNA sequencing.
Cell culture and transient transfections COS-7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin (cell culture medium). Cells were grown at 37 8C in a humidified 5% CO 2 incubator. Depending on the number of cells seeded, cells were The amino acid residues that were deleted or present in the receptor variants are outlined. The amino acid residue positions refer to the human LHR and to the human V 2 R (without epitope tags). Single amino acid substitutions and sequences of receptor chimeras are also indicated.
transfected with various amounts of DNA using METAFECTENE or FUGENE according to the manufacturer's instructions.
Membrane preparation, SDS-PAGE and western blot analysis
Sixty hours after transfection, cells from two 10-cm dishes were washed twice in ice-cold PBS and scraped into lysis buffer (25 mM Tris/HCl, pH 7 . 5, 1 mM EDTA, 1 tablet COMPLETE MINI in 7 ml volume). After 5 min on ice, cells were homogenized by passing the cell suspension six times through a 0 . 5 mm!25 mm needle attached to a disposable syringe. The lysate was then centrifuged at 600 g for 10 min at 4 8C. The supernatant was centrifuged at 100 000 g for 1 h at 4 8C. The pellet was resuspended in 200 ml lysis buffer, snap-frozen in liquid N 2 and stored at K80 8C. To prevent glycosylation, after transfection COS-7 cells were incubated with 2 mM tunicamycin for 14 h. Protein concentrations of membrane fractions were determined by the DC PROTEIN ASSAY. After addition of 2! SDS/sample buffer to the probes 75 or 100 mg protein were resolved on 7, 8, or 12% SDS polyacrylamide gels under reducing conditions without boiling. After transfer of proteins to HYBOND C EXTRA membranes, blots were incubated with ROTI-BLOCK blocking reagent at room temperature for 1 h or overnight at 4 8C. Blots were washed in PBS and then probed with 50 mU/ml of an HRP-labeled rat monoclonal anti-HA antibody (3F10, Roche Diagnostics) in PBS containing 5% dry milk at room temperature for 1 h. In contrast, blots of lysates from cells expressing LHR fused to CGba were incubated with a 1:4000 dilution of a rabbit anti-CGb antiserum in PBS containing 5% dry milk and then probed with a dilution of an HRP-labeled goat anti-rabbit IgG (A-6154, Sigma) in PBS containing 5% dry milk. After washing, signals were visualized by using the ECL detection system.
Cell surface ELISA and immunofluorescence studies
To evaluate cell surface expression of receptors carrying an HA-tag, we used an indirect cellular ELISA (Schoneberg et al. 1997) , further referred to as cell surface ELISA. COS-7 cells were seeded into 24-well plates and transfected with 0 . 6 mg DNA and 1 . 8 ml METAFECTENE per well. To examine plasma membrane targeting concomitantly with cAMP levels, COS-7 cells were seeded into 10 cm-dishes, transfected with the cDNA of various LHR variants (2-12 mg cDNA per 10-cm dish) using METAFECTENE or FUGENE according to the manufacturer's instructions, and then harvested and seeded into 24-well plates (ELISA) and 12-well plates (cAMP accumulation assay). Forty eight hours after transfection, cells in 24-well plates were fixed with a 10% formalin solution without disrupting the cell membrane, blocked with DMEM supplemented with 10% fetal bovine serum, and then incubated with the same medium containing a mouse monoclonal anti-HA antibody (12CA5, Roche Diagnostics). After washing with PBS, cells were incubated with an HRP-conjugated anti-mouse antibody (A-4416, Sigma) in DMEM containing 10% fetal bovine serum for 1 h. Cells transiently expressing LHR fused to CGba were first incubated with a 1:4000 dilution of a rabbit anti-CGb antiserum in DMEM containing 10% fetal bovine serum and then probed with an HRP-labeled goat anti-rabbit IgG (A-6154, Sigma). After washing, cells were incubated with 1-STEP TURBO TMB-ELISA containing TMB (3,3 0 ,5,5 0 tetramethylbenzidine), a substrate for HRP. The enzymatic reaction was stopped by the addition of 1 M H 2 SO 4 , and color development was measured at 450 nm using an ELISA reader (ELX800G, MWG Biotech). The A 450 nm readings of untransfected cells were subtracted from A 450 nm readings of cells expressing HA-tagged receptors.
To examine subcellular distribution of wild type and mutant LHR, immunofluorescence studies were carried out. COS-7 cells were grown on sterilized, 25 mm glass coverslips in 6-well plates and transfected with 2 . 5 mg DNA and 7 . 5 ml METAFECTENE per well. At 24 or 48 h after transfection, cells were fixed with 10% formalin, probed with 1 mg/ml of a monoclonal rat anti-HA antibody (3F10; Roche Diagnostics), and then incubated with a fluorescein isothiocyanate-labeled anti-rat antibody (F 1763, Sigma). To detect intracellularly retained receptors, cells were preincubated with 0 . 1% Triton X-100 in PBS for 30 min. Fluorescence microscopy was performed with a confocal laser scanning microscope (LSM 510 META; Zeiss, Jena, Thuringen, Germany).
cAMP accumulation assays
For cAMP accumulation assays, COS-7 cells were seeded into 12-well plates (0 . 7-1!10 5 COS-7 cells/well) and transfected with 0 . 5 mg DNA and 1 . 5 ml METAFECTENE per well. To examine plasma membrane targeting concomitantly with cAMP levels, COS-7 cells were seeded into 10-cm dishes, transfected with the cDNA of various LHR variants (2-12 mg cDNA per 10-cm dish) using METAFECTENE or FUGENE according to the manufacturer's instructions, and then harvested and seeded into 24-well plates (ELISA) and 12-well plates (cAMP accumulation assay). About 24-48 h after transfection, cells in 12-well plates were prelabeled with 2 mCi/ml of 3 H-adenine (31 . 7 Ci/mmol, PerkinElmer Life Science, Boston, MA, USA) and incubated overnight. About 18-22 h after labeling, cells were washed once in serum-free DMEM supplemented with 1 mM 3-isobutyl-1-methylxanthine, followed by incubation with the same medium containing 1 mM hCG (Calbiochem), 100 mU/ml bTSH (Sigma) or 100 mM forskolin (Biotrend) for 1 h as indicated in the figure legends. Thereafter, the medium was discarded and cells were lysed by the addition of 5% trichloroacetic acid containing 1 mM cAMP and 1 mM ATP. cAMP separation was carried out according to Salomon et al. (1974) and cAMP production as measured by liquid scintillation spectrometry was normalized to basal cAMP accumulation by the wild type LHR. Basal cAMP accumulation of cells expressing V2LHR, V2hingeLHR or the wild type LHR is given as percentage of forskolin (100 mM)-induced cAMP accumulation determined in cells derived from the same transfection. Basal cAMP accumulation of mock transfected cells was subtracted from the measured cAMP values.
Results
The ectodomain is required for LHR activation
The ECD of glycoprotein hormone receptors is capable of high-affinity hormone binding (Xie et al. 1990 , Braun et al. 1991 , Moyle et al. 1994 , Bhowmick et al. 1996 , Thomas et al. 1996 , Hong et al. 1999a ,b, Ascoli et al. 2002 , Smits et al. 2003 , Vassart et al. 2004 , Fan & Hendrickson 2005 , whereas G protein activation and signal propagation is mediated by the heptahelical TMD (Ascoli et al. 2002 , Vassart et al. 2004 ). However, both domains cooperate in intramolecular signal transmission. Thus, the concept has been put forward that the ECD of the TSHR acts as an inverse agonist to constrain the TMD in an inactive conformation (Zhang et al. 1995 , Van Sande et al. 1996 , Vlaeminck--Guillem et al. 2002 . To investigate whether this is also the case for the human LHR, a receptor mutant (V2LHR) lacking the complete ECD was examined (Table 1; Sangkuhl et al. 2002) . To achieve sufficient cell surface expression of this mutant, the first 39 amino acid residues of the human V 2 R were N-terminally fused to the TMD. Additionally, to test whether the 'hinge region', the TMD-proximal part of the LHR-ECD, is essential for receptor activation, we created a mutant (V2hingeLHR) lacking the N-terminal part of the ECD but retaining the 'hinge region', to which the aforementioned V 2 R tag was added (Table 1) . A HA-tag was inserted into the truncated mutants and the wild type receptor to allow for immunological detection of the receptor proteins (see Materials and methods).
First, we tested the protein expression of the wild type receptor (LHR wt) and the V2LHR mutant in COS-7 cells transfected with the appropriate cDNA using western blot analysis. Total membrane preparations derived from COS-7 cells expressing LHR wt or V2LHR revealed bands of 85 or 40 kDa respectively, which did not appear in membrane fractions of non-transfected or mocktransfected cells indicating the specific detection of the glycosylated form of both proteins with the expected molecular mass (Fig. 1A ; Ascoli et al. 2002) . Tunicamycin treatment of cells expressing the wild type LHR or V2LHR reduced the apparent molecular mass to the expected size of both non-glycosylated proteins (LHR wt: 68 kDa vs V2LHR: 38 kDa) indicating inhibition of N-linked glycosylation. In addition, high molecular weight bands were detected in COS-7 cells expressing the V2LHR mutant, which most probably represent oligomers of this receptor. Identification of the glycosylated form of V2LHR suggests that this truncated protein undergoes protein maturation in COS-7 cells as well as the wild type LHR. To investigate proper targeting of V2LHR to the plasma membrane, we performed immunofluorescence microscopy experiments with intact COS-7 cells expressing the wild type LHR or V2LHR. In both cases, cell surface expression was detected (Fig. 2) , indicating correct targeting of the V2LHR variant to the plasma membrane. To quantify plasma membrane expression of V2LHR and V2hingeLHR, ELISA experiments were performed. These analyses revealed that cell surface expression of V2LHR and V2hingeLHR was similar to that of the wild type LHR (Fig. 1B) . These data show that both truncated LHR are expressed in COS-7 cells and that a detectable amount of receptors is translocated to the plasma membrane.
To explore the role of the LHR-ECD on basal receptor activity, we investigated the signal transduction properties via the adenylyl cyclase pathway. To this end, we determined agonist-independent cAMP accumulation in COS-7 cells expressing LHR wt, V2LHR or V2hin-geLHR. Since intracellular cAMP accumulation depends both on basal receptor activity and the amount of functional receptors targeted to the plasma membrane, we determined specific receptor activities (SRA), which were defined as the ratio of the receptor-dependent cAMP accumulation and the corresponding cell surface expression level. The wild type LHR exhibited an SRA of 12 . 2G3 . 2 (Fig. 1D) . Surprisingly, the SRA of both truncated receptors was not increased compared with the wild type value. In fact, the SRA of V2LHR (8 . 3G1 . 9) was decreased by 32% compared with the wild type SRA.
In addition, V2hingeLHR revealed an SRA (6 . 1G1 . 0), which was reduced by 50% compared with the wild type value. These findings indicate that removal of the ECD does not enhance basal LHR activity, and thus, that the ECD in the case of the LHR does not serve as a tethered inverse agonist. These results are in line with previous studies (Sangkuhl et al. 2002 , Karges et al. 2005 and in clear contrast to the model proposed for the TSHR (Zhang et al. 1995 , Van Sande et al. 1996 , Vlaeminck-Guillem et al. 2002 . The absence of the ECD in V2LHR or the partial deletion of the ECD in V2hingeLHR reduced basal receptor activity, suggesting a putative role of the ECD as a positive, but not as a negative regulator of receptor activity. 
An intact ectodomain is required for ligand-dependent receptor activation
In cAMP accumulation assays hCG treatment of cells expressing the wild type LHR resulted in a 17 . 6-fold elevated cAMP level compared with the basal cAMP value (Fig. 1E) . In contrast, none of the truncated receptors (V2LHR or V2hingeLHR) responded to hCG with cAMP increase. To exclude the possibility that the lack of agonist-dependent activation of truncated LHR was caused by low agonist affinity due to a missing hormone binding domain, fusion proteins between a CGβα-LHR∆aa199-267 Figure 2 To examine subcellular localization of heterolous expressed wild type and mutant LHR, COS-7 cells were grown on glass cover slips and transfected with wild type or mutant LHR cDNA. After 48 h, immunofluorescence studies were performed as described under Materials and methods. Intact and permeabilized cells were incubated with a monoclonal rat anti-HA antibody, and then probed with a fluorescein isothiocyanate-labeled anti-rat secondary antibody. In contrast, cells expressing receptors linked to CGba were incubated with a rabbit anti-CGb antiserum and then probed with a fluorescein isothiocyanate-labeled anti-rabbit secondary antibody. Images of fluorescein isothiocyanate fluorescence (FITC), the corresponding differential interference contrast images (DIC), and overlays of both are depicted (scale bars, 10 mm). Each picture is a typical representative of two independent experiments.
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www.endocrinology-journals. single-chain variant of hCG (CGba) and the full-length LHR (CGba-LHR wt) or truncated receptor variants (CGba-V2LHR and CGba-V2hingeLHR) were constructed (Table 1) . In a previous study it has been shown that this single-chain hCG activates the LHR as efficiently as the native hormone (Sugahara et al. 1995) .
To avoid sterical hindrance within the CGba-V2LHR fusion protein in which the single-chain hCG might be fixed in a rigid position that forestalls productive interaction with the TMD, we introduced a linker sequence between tethered CGba and the LHR-TMD by inserting the major portion of the ECD (amino acid residues 108-404) of the distantly related relaxin receptor LGR7 (CGba-V2GR7LHR) (Table 1) . First, we examined protein expression of hormonereceptor variants by Western blot analysis (Fig. 3A) . Membrane preparations of cells transfected with CGba-LHR wt cDNA contained a protein with an apparent molecular mass of 115 kDa (Fig. 3A, lane 1 ). An additional high-molecular mass protein (around 200-250 kDa) of unknown composition was also discernible (lane 1). Analysis of membrane preparations obtained from cells expressing CGba-V2LHR revealed a specific band with an expected molecular mass of 70 kDa and an additional broad band of about 160 kDa (lane 2). The high-molecular mass proteins might represent oligomeric forms of the hormone-receptor fusion proteins. To visualize plasma membrane targeting of hormone-receptor chimeras, immunofluorescence experiments were performed with an antiserum raised against the b-subunit of hCG. In these analyses, CGba-LHR wt and CGba-V2LHR were detected at the cell surface of COS-7 cells (Fig. 2) . ELISA experiments revealed that truncated LHR fused to CGba were expressed at the cell surface to 68-81% of the CGba-LHR wt expression (Fig. 3B) .
To examine hCG-promoted signaling properties of CGba-LHR wt compared with the unmodified wild type receptor, concentration-response curves of cAMP accumulation were determined (Fig. 3C) . In these analyses, hCG activated the wild type LHR with an EC 50 value of 2 . 0 nMG0 . 2, whereas in the case of CGba-LHR wt, the half-maximally effective agonist concentration was shifted towards higher concentrations by a factor of 47 (EC 50 Z93 nMG0 . 2), most likely reflecting steric hindrance imparted by the fused single-chain gonadotropin. These data are in clear contrast to previous studies (Narayan et al. , 2002 showing that a similar fusion protein between the hCG and the LHR connected via a flexible linker containing the CTP region of the hCG is not further activated by endogenous hCG. Thus, we generated two additional hCG-LHR fusion proteins: one harboring the CTP region of the hCG between the CGba and the LHR wt (CGba-CTP-LHR wt) and a second one lacking again the entire ECD of the LHR (CGba-CTP-V2LHR; Table 1) . Surprisingly, both constructs showed a significant increase in cell surface expression when compared with the hormone wild type LHR variant without the CTP (CGba-LHR wt; Fig. 3B ). In terms of SRA, CGba-LHR wt (2 . 6G0 . 2) and CGba-CTP-LHR wt (3 . 8G0 . 4) clearly exhibited high basal SRA (Fig. 3E) when compared with the LHR wt. Interestingly, in line with the previous studies (Narayan et al. , 2002 , for the CGba-CTP-LHR wt fusion protein no further increase in cAMP production was observed after adding exogenous hCG. Thus, these constructs allowed us to examine the consequences of ECD truncation or deletion for receptor activity in the presence of a tethered agonist. All constructs lacking the ECD of the LHR: CGba-V2LHR (SRA: 1 . 0G0 . 1), CGba-V2hingeLHR (SRA: 1 . 1G0 . 1), CGba-V2LGR7LHR (SRA: 1 . 2G0 . 1) and CGba-CTP-V2LHR (SRA: 0 . 4G0 . 02) did not show an increased SRA under basal conditions, clearly indicating that an intact LHR-ECD is required for ligand-dependent receptor activation and that the hormone per se is unable to activate the TMD.
Deletion of LRR leads to a loss of function of hormone-receptor fusion proteins
A prominent structural feature of the ECD of the LHR and related glycoprotein hormone receptors is the presence of ten LRR (Fan & Hendrickson 2005 ). There Figure 3 Fusion proteins between single-chain hCG and wild type or truncated receptors were expressed in COS-7 cells, and Western blot analyses (A) as well as ELISA experiments (B) and cAMP accumulation assays (C and D) were performed as described under Materials and methods. (A) To detect hormone-receptor variants in membrane preparations, Western blots were incubated with a rabbit anti-CGb antiserum and thereafter with an HRP-labeled anti-rabbit antibody. (B) Cell surface expression of hormone-receptor mutants was quantified in ELISA assays and compared with the plasma membrane targeting signal of CGba-LHR wt. Receptors were detected by using a rabbit anti-CGb antiserum and an HRP-labeled anti-rabbit secondary antibody. Data are presented as meansGS.E. of A 450 nm readings of least three independent experiments, each carried out in triplicate. (C) hCG-stimulated cAMP accumulation in COS-7 cells expressing CGba-LHR wt or the wild type LHR was determined. cAMP formation is expressed as -fold over basal cAMP production of the wild type LHR. Representative concentration-response curves of five independent experiments, each carried out in duplicate, are shown. (D) Basal and agonist-induced cAMP formation of hormone-receptor proteins are expressed as -fold over basal cAMP production of the wild type LHR. Data are presented as meansGS.E. of two to twelve independent experiments, each carried out in duplicate or triplicate. Dashed line indicates basal cAMP value of the wild type LHR. (E) Specific receptor activity (SRA) of each variant was determined by normalizing basal and agonist-induced cAMP levels to cell surface expression. To this end, cAMP levels (D) were normalized to the cell surface expression of each construct (B), whereas the ELISA signal (A 450 nm ) of CGba-LHR wt was arbitrarily set to 1. Data are depicted as meansGS.E.
is ample experimental evidence to suggest that the N-terminal LRR are required for hormone binding (Braun et al. 1991 , Bhowmick et al. 1996 , Thomas et al. 1996 , Ascoli et al. 2002 , Fan & Hendrickson 2005 , whereas the effect of the C-terminal LRR on hCG binding affinity remained controversial (Braun et al. 1991 , Thomas et al. 1996 , Ascoli et al. 2002 , Fan & Hendrickson 2005 . Thus, we sought to define the role of the C-terminal LRR, i.e. LRR 8-10 according to 
t r a n s f e c t e d
A 3 colleagues, (Fan & Hendrickson 2005) , in the regulation of LHR activity. Truncated LHR mutants in which discrete LRR were deleted have been shown to be retained intracellularly and could therefore not be studied functionally (Thomas et al. 1996) . To avoid this problem, we deleted amino acid residues from 199 to 267 (LRR 8-10) within the fusion protein consisting of hCG and the wild type LHR (CGba-LHRDaa199-267) to promote cell surface expression of these LHR 8-10 deficient receptor mutants. Thus, our aim was to identify putative structures within LRR 8-10 crucial for the formation of active receptor states (Table 1) . ELISA experiments revealed that CGba-LHRDaa199-267 was expressed at the cell surface to about 70% of the expression level of CGba-LHR wt (Fig. 4A) . Immunofluorescence stainings of CGba-LHRDaa199-267 (Fig. 2) confirmed surface ELISA data indicating efficient membrane trafficking. Furthermore, membrane fractions of COS-7 cells expressing CGbaLHRDaa199-267 were subjected to Western blot analysis and compared with membrane preparations of COS-7 cells transfected with CGba-LHR wt or CGba-V2LHR cDNA (Fig. 3A) . A specific band with an apparent molecular mass of 110 kDa was detected in cells expressing CGba-LHRDaa199-267 (Fig. 3A, lane 3) commensurate with the estimated molecular mass. Additionally, a diffuse band in the high-molecular weight range (O180 kDa) was detected, most probably representing an oligomeric cluster of the receptor. In contrast, to CGba-LHR wt, CGba-LHRDaa199-267 expressed in COS-7 cells did not exhibit an increased basal or agonist-induced SRA (Fig. 4C) . This result was compatible with our earlier hypothesis, and we assumed at this stage that the lack of cAMP responsiveness was due to a missing agonistic structure located in the C-terminal LRR (LRR 8-10). By deleting various portions of the region between amino acid residues 199 and 267, we sought to further narrow down a potential endogenous agonistic structure or a structure contributing to agonistpromoted receptor activity respectively (Table 1) .
To point out possible functional differences between the N-terminal LRR (e.g. LRR 3) and the C-terminal LRR (LRR 8-10), we generated an additional mutant hormone-receptor protein lacking amino acids from 100 to 124 within LRR 3 (CGba-LHRDaa100-124), which is thought to participate in hormone binding Basal cAMP accumulation (-fold over LHR wt basal) (C) Specific basal and agonist-dependent receptor activity of each variant was determined by normalizing basal and agonist-induced cAMP levels to cell surface expression. cAMP levels were divided by the receptor-dependent signal of A 450 nm readings in cell surface ELISA, whereas the signal of A 450 nm readings of CGba-LHR wt was arbitrarily set to 1. Data are depicted as meansGS.E.
( Thomas et al. 1996 , Ascoli et al. 2002 , Fan & Hendrickson 2005 . However, deletion of LRR 3 hampered the tethered agonist to activate the receptor, as indicated by the low basal SRA levels observed for the CGba-LHRDaa100-124 mutant (Fig. 4C ). These data indicate that deletions in the N-terminal or C-terminal region of the LRR lead to a misfolded ECD, which is not able to stabilize an active receptor conformation. Further, no continuous linear agonistic structure in the C-terminal LRR region could be defined suggesting that the integrity of the ECD is required for agonistinduced receptor activation.
The ectodomain stabilizes an activation-competent receptor conformation
Removal of the ECD from the TMD of the LHR led to a slightly decreased basal receptor activity compared with the full-length receptor. Unfortunately, basal activity of the LHR is rather low compared with other GPCR. Therefore, we took advantage of naturally occurring activating point mutations of the LHR that result in dramatically increased agonist-independent receptor activity of the wild type LHR (Laue et al. 1995 , Yano et al. 1996 , Latronico et al. 1998 , Muller et al. 1998 , Kremer et al. 1999 , Liu et al. 1999 . Four different point mutations (L457R in TMD-3, D564G in IL-3, D578H and D578Y in TMD-6; details in Table 1) were integrated into V2LHR, and these mutants were compared with their full-length LHR counterparts. In line with previous reports (Laue et al. 1995 , Yano et al. 1996 , Latronico et al. 1998 , Muller et al. 1998 , Kremer et al. 1999 , Liu et al. 1999 , all mutations inserted into the full-length LHR resulted in significantly increased basal SRA (6 . 7-44 . 1) as compared with the SRA of the wild type without any mutation (Fig. 5C ). In contrast, only one mutation (D578H) evoked high agonist-independent SRA in the absence of the ECD (V2LHR-D578H: SRA Z 9 . 9G0 . 5). After deletion of the ECD, the effect of the mutations L457R, D564G and D578Y on receptor activity was dramatically reduced as compared with their effect in the wild type receptor. The basal SRA of the truncated LHR harboring the L457R-mutation was decreased to 47%G3 . 4 of the SRA of the wild type LHR containing the same mutation. Furthermore, V2LHR-D564G and V2LHR-D578Y exhibited a basal SRA of 6 . 3%G0 . 7 or 22 . 4%G1 . 5 of the SRA value of their wild type counterparts harboring the same mutation respectively. The data observed for the D578H-mutation suggest that ECD-deficient LHR principally have the potential to activate the G s pathway and are not inactive per se. However, these receptors cannot be mutationally activated as efficiently as the wild type LHR. The ECD may be necessary to stabilize a distinct conformation of the heptahelical portion, prone to be rendered constitutively active by missense mutations. Since this hypothesis is in clear contrast to the model proposed for the closely related TSHR, we questioned whether the TSHR-ECD would render the LHR-TMD activation-competent for heptahelical activating mutations in the same way as the native LHR-ECD or whether it would act as a tethered inverse agonist on the LHR-TMD as observed for the wild type TSHR. Therefore, we attached the TSHR-ECD (amino acid residues 1-413) to the truncated LHR harboring the above mentioned activating point mutations (Table 1) . Two of these resulting TSHR-LHR chimeras (TSHR-LHR-D578H and TSHR-LHR-D578Y) were tested in immunofluorescence studies, and both mutants were detected on the cell surface (Fig. 2) .
As reported earlier, analogous TSHR-LHR chimeras are able to bind TSH and can be stimulated by TSH (Braun et al. 1991) . Indeed, in our hands all TSHR-LHR constructs responded to 100 mU/ml bTSH with a 4-to 11-fold increase in cAMP formation as compared with the basal cAMP value of the wild type LHR (Fig. 5B) . Interestingly, TSHR-LHR chimeras harboring activating TMD-mutations showed significantly reduced basal SRA as compared with their wild type LHR counterparts (Fig. 5C ). However, SRA of TSHR-LHR constructs were slightly higher than those of the V2LHR variants. Solely, the D578H-mutation inserted into the TSHR-LHR sequence induced strong constitutive receptor activity. To summarize, the propensity of three out of four activating TMD-mutations to induce high basal receptor activity was dramatically reduced in the absence of the LHR-ECD. Furthermore, the TSHR-ECD was not fully sufficient to render the LHR serpentine domain activation-competent for activating mutations, and therefore could not functionally replace the LHR-ECD.
To address the question whether an intact LHR-ECD would be necessary to facilitate the formation of active receptor states induced by agonist action or activating mutations, several naturally occurring activating mutations located within the sixth a-helical membrane-spanning domain (D564G, D578H, D578Y) were introduced into two LRR-deletion variants of the CG-receptor fusion protein (CGba-LHRDaa199-223 and CGba-LHRDaa199-244) and CGba-LHR wt (Table 1) . CGba-LHR wt constructs comprising TMDmutations exhibited SRA of 1 . . 7. However, LRRdeletion mutants harboring TMD-mutations revealed significantly decreased SRA compared with their CGba-LHR wt counterparts (Fig. 6C) , indicating that deletions in the LRR result in a misfolded ECD and thus abolish the ability of the ECD to support the action of activating mutations.
Taken together, these data support the overall concept that the ECD contributes to the formation of an active receptor state and that it facilitates agonist action and the properties of naturally occurring activating mutations. Receptors were detected by using an antibody system against the HA-tag of the receptors. Data are presented as meansGS.E. of A 450 nm readings of at least three independent experiments, each carried out in triplicate. (B) In cAMP accumulation assays, cells expressing receptor variants of LHR or V2LHR structure were incubated with or without 1 mM hCG, whereas cells expressing TSHR-LHR chimeras were treated with or without 100 mU/ml bTSH. Basal and agonist-induced cAMP values are expressed as -fold over basal cAMP production of the wild type LHR. Data are depicted as meansG S.E. of at least three independent experiments, each carried out in duplicate. (C) Specific basal and agonist-dependent receptor activities (SRA) of each variant were determined by normalizing basal and agonist-induced cAMP levels to cell surface expression. cAMP levels were divided by the receptor-dependent signal of A 450 nm readings in cell surface ELISA, whereas the signal of A 450 nm readings of LHR wt was arbitrarily set to 1. Data are depicted as meansGS.E.
Discussion
A detailed understanding of the mechanism of glycoprotein hormone receptor activation is helpful for the development of new pharmacological tools for therapeutic intervention. Principle aspects of glycoprotein hormone receptor activation have been thoroughly investigated over the past years, but the exact mechanism is still a moot issue. Our data provide evidence for the contribution of the ECD of the LHR to adenylyl cyclase activation induced by agonist or activating point mutations suggesting that the ECD stabilizes a receptor conformation prone to be activated by naturally occurring mutations or the cognate agonist. In this context, the integrity of the ECD, particularly the intactness of the LRR domain is a prerequisite for the ability of the LHR-ECD to stabilize an activation-competent receptor conformation. The ECD of the closely related TSHR is not fully sufficient to render the LHR-TMD susceptible to activating mutations. Thus, the function of the ECD may differ between the glycoprotein hormone receptors. To summarize, our findings highlight an as yet unappreciated role of the ECD pertinent to LHR activation by agonist and by naturally occurring mutations.
LHR ectodomain does not serve as an endogenous inverse agonist
Due to observations made in the TSHR, several studies support an activation model in which the ECD of glycoprotein hormone receptors functions as a tethered inverse agonist constraining the receptor in an inactive state (Zhang et al. 1995 , Van Sande et al. 1996 , Vlaeminck-Guillem et al. 2002 . This hypothesis is corroborated by findings that gentle treatment of cells expressing the TSHR with trypsin results in agonist-independent receptor activation (Van Sande et al. 1996) . In contrast, we report here for the LHR that removal or partial deletion of the ECD by genetic engineering does not result in any detectable increase in basal LHR activity. In fact, deletion of the ECD tended to reduce LHR activity, indicating a specific and distinct role of the ECD among the different glycoprotein hormone receptors. The observation that removal of the LHR-ECD does not induce constitutive receptor activity is further supported by recent observations that cAMP production of the wild type LHR after chemical shedding of the ECD from the TMD remains at a low level (Karges et al. 2005) . These findings are consistent with previous data (Sangkuhl et al. 2002 , Karges et al. 2005 and thus, the role of the ECD for LHR activation appears to differ from the situation for the TSHR (Zhang et al. 1995 (Zhang et al. , 2000 , Van Figure 6 Various LRR were deleted from single-chain hCG/LHR constructs containing naturally occurring activating TMD-mutations, and the resulting mutants were expressed in COS-7 cells. (A) Cell surface expression of mutant receptors was quantified in ELISA experiments and compared with the plasma membrane targeting signal of CGba-LHR wt. Receptors were detected by using a rabbit anti-CGb antiserum and an HRP-labeled anti-rabbit secondary antibody. Data are presented as meansGS.E. of A 450 nm readings of two to three independent experiments, each carried out in triplicate. (B) Basal and agonist-dependent cAMP accumulations were determined. cAMP levels are expressed as -fold over basal cAMP production of the wild type LHR. Data are presented as meansGS.E. of two to three independent experiments, each carried out in duplicate. Dashed line indicates the basal cAMP level of the wild type LHR. (C) Specific basal and agonist-dependent receptor activity of each variant was determined by normalizing basal and agonistinduced cAMP levels to cell surface expression. cAMP levels were divided by the receptor-dependent signal of A 450 nm readings in cell surface ELISA, whereas the signal of A 450 nm readings of CGba-LHR wt was arbitrarily set to 1. Data are depicted as meansGS.E. Sande et al. 1996 , Vlaeminck-Guillem et al. 2002 ).
An intact ectodomain is required for ligand-dependent receptor activation
To exclude the possibility that the lack of agonistdependent activation of N-terminally truncated LHR was based upon extremely low agonist affinity due to a missing hormone-binding domain, several fusion proteins between single-chain hCG and LHR variants were generated and functionally analyzed. These hormone-receptor chimeras allowed us to study the influence of the complete ECD or parts of the ECD on receptor activity in the presence of the agonist, in our case a tethered agonist.
As expected from previous studies (Narayan et al. , 2002 , fusion of single-chain hCG to the fulllength LHR resulted in receptors with high constitutive activity. In contrast, none of the truncated receptor mutants fused to hCG (CGba-V2LHR, CGba-V2hin-geLHR, CGba-V2LGR7LHR and CGba-CTP-V2LHR) displayed constitutive or agonist-induced activity (Fig. 3E) . At least two straightforward explanations may account for this observation: first, determinants in the ECD may be required to induce a conformational change in the ligand, a structural rearrangement that was shown to occur following binding of FSH to its hormone-binding domain (Fan & Hendrickson 2005) . These receptor-induced conformational changes in the loops of one or both subunits of the hormone as well as in the C-terminus of the common a-subunit may be critical for TMD activation and may be absent in truncated variants (CGba-V2LHR, CGba-V2hingeLHR and CGba-CTP-V2LHR) lacking an LRR-containing hormone-binding domain. However, it should also be taken into consideration that single-chain glycoprotein hormone analogs apparently display remarkable conformational flexibility. Accordingly, 'multisubunit' variants harboring CG, FSH and TSH activity due to the combination of b-subunit domains are biologically active in vitro and in vivo (Garcia-Campayo et al. 2002 , 2004 , Ben-Menahem 2004 . Secondly, the activation determinants for the TMD may be localized in the ligand and in the ECD or even in the ECD alone. Thus, in the absence of the N-terminal portion of the ECD, the LRR region or the 'hinge region', it may not be possible to elicit an adequate conformational change in the TMD allowing for productive coupling to G s .
To test the possibility that the spacing between singlechain hormone and the receptor was insufficient in the truncated hormone-receptor fusion construct (CGba-V2LHR) thereby precluding activation of the serpentine domain, we integrated a long linker between the tethered hormone and the truncated LHR. The resulting construct CGba-V2LGR7LHR contained a linker which consisted of the major part of the ECD of hLGR7, a member of the LGR family (Hsu et al. 2000 , Herpin et al. 2004 . The ECD of hLGR7 is thought to attain a similar overall fold as gonadotropin receptor ECD, whereas the degree of primary sequence identity is low (Hsu et al. 2000) . When analyzed functionally, CGba-V2LGR7LHR also failed to stimulate cAMP production, suggesting that an intact endogenous ECD is required for ligand-dependent receptor activation and that the hormone per se is unable to activate the TMD.
No agonistic structure is identifiable within the LRR It is well established that the N-terminal part of the LRR domain is critical for ligand binding (Braun et al. 1991 , Bhowmick et al. 1996 , Thomas et al. 1996 , Ascoli et al. 2002 , Fan & Hendrickson 2005 . However, conflicting data on the contribution of the C-terminal part of the LRR domain to hormone binding have been published (Braun et al. 1991 , Thomas et al. 1996 , Ascoli et al. 2002 , Fan & Hendrickson 2005 . We reasoned that if the C-terminal LRR are dispensable for hormone binding, they may harbor a structural module functioning as a tethered agonist for the TMD providing an explanation why fusion proteins between hCG and truncated receptors lacking these LRR are inactive. To circumvent the problem that N-terminally truncated LHR constructs are mainly trapped intracellularly (Thomas et al. 1996) , we deleted various parts of the C-terminal LRR within the hormone-receptor fusion constructs to identify possible agonistic structures within the ECD of glycoprotein hormone receptors. The LRR-deletion mutants devised in our study were efficiently delivered to the cell surface as measured by ELISA with an antiserum against the b-subunit of hCG. This effect may be attributed to plasma membrane targeting mediated by the tethered hormone. Thus, functional characteristics of the different LRR-deletion mutants could be directly compared with the wild type LHR for the first time. Taking cAMP accumulation as readout, none of the deletion mutants revealed constitutive or agonistinduced receptor activity (Fig. 4C) . Partial removal of LRR lead to a total loss of the elevated cAMP accumulation elicited by CGba-LHR wt expression indicating that an intact ECD comprising all LRR is required for agonist-dependent receptor activation.
Contrary to other class A G protein-coupled receptors, hormone binding to the ECD occurs with high affinity in the absence of the TMD (Rapoport et al. 1998 , and the TMD will allow the correct orientation of these two receptor modules towards each other and will grant valuable insight into the mechanism of glycoprotein hormone receptor activation.
